Oncology Corporate Profile
BeyondSpring Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. BeyondSpring is focused on the advancement and commercialization of Plinabulin, a novel, Phase 3-ready cancer therapeutic initially targeting non-small-cell lung cancer (NSCLC).
|Brand / Product||Class||Area of Study||Phase||Partnership|
|plinabuin (+ docetaxel)||synthetic analogue||Non Small Cell Lung Cancer (NSCLC)||III|
|plinabuin (+ nivolumab)||synthetic analogue||Non Small Cell Lung Cancer (NSCLC)||I|
|plinabuin (+ radiation)||synthetic analogue||Glioma||Preclinical|
|plinabuin (+ docetaxel)||synthetic analogue||KRAS Mutant Non Small Cell Lung Cancer (NSCLC)||Preclinical|
View additional information on product candidates here »